91 related articles for article (PubMed ID: 24579214)
1. [Emergence of entecavir genotypic resistance in a nucleoside naive chronic hepatitis B patient who had been treated for nearly five years: a case report].
Liu F; Wang XW
Zhonghua Gan Zang Bing Za Zhi; 2013 Oct; 21(10):781-2. PubMed ID: 24579214
[No Abstract] [Full Text] [Related]
2. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
Suzuki F; Akuta N; Suzuki Y; Yatsuji H; Sezaki H; Arase Y; Kawamura Y; Hosaka T; Kobayashi M; Ikeda K; Kobayashi M; Watahiki S; Kumada H
J Clin Virol; 2007 Jun; 39(2):149-52. PubMed ID: 17442615
[No Abstract] [Full Text] [Related]
3. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
Zoulim F
Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
[No Abstract] [Full Text] [Related]
5. Five-year data released for entecavir.
AIDS Patient Care STDS; 2008 Apr; 22(4):349. PubMed ID: 18422464
[No Abstract] [Full Text] [Related]
6. [Hepatitis B virus resistance to entecavir].
Hidalgo-Tenorio C; Rivero M; Alvarez M; García F
Med Clin (Barc); 2012 Jul; 139(5):228-9. PubMed ID: 22401720
[No Abstract] [Full Text] [Related]
7. Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient.
Lee HW; Kim HJ; Hong SP; Cha BK; Chang HY; Choi CH; Do JH; Kim JG; Chang SK
Intervirology; 2012; 55(5):380-4. PubMed ID: 22538265
[TBL] [Abstract][Full Text] [Related]
8. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
9. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
Cheng PN; Chang TT
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
[TBL] [Abstract][Full Text] [Related]
12. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
[TBL] [Abstract][Full Text] [Related]
13. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
14. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
15. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
16. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
[TBL] [Abstract][Full Text] [Related]
17. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
[TBL] [Abstract][Full Text] [Related]
19. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
20. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
